incyte | Biopharmaceutical Company | Solutions for Unmet Medical Needs

Keyword	CPC	PCC	Volume	Score	Length of keyword
incyte	0.9	0.1	5251	29	6

Keyword	CPC	PCC	Volume	Score
incyte	1.89	0.8	8705	14
incyte corporation	1.06	0.2	1482	28
incyte stock	1.45	1	4905	58
incyte diagnostics	0.03	0.4	6533	53
incytecares	0.95	0.8	5889	77
incyte pharmaceuticals	0.59	0.4	3409	24
incyte stock news	0.39	0.4	732	85
incyte pipeline	1.33	0.5	6141	49
incyte careers	0.65	0.7	7111	85
incyte pathology	1.42	0.5	9373	2
incyte lab test menu	1.8	0.6	2541	2
incytediagnostics itx	0.04	0.5	3505	68
incyte stock price	0.9	0.5	120	17
incytediagnostics.ixt.com	1.12	0.8	1649	61
incyte lab	0.12	0.3	9751	97
incyte test menu	0.24	0.3	6051	53
incyte biosciences	1.87	1	5766	11
incyte diagnostics spokane	1.32	0.8	4125	33
incyte yverdon	0.03	0.1	4103	30
incyte annual report	1.43	0.9	7144	24

Search Results related to incyte on Search Engine

Biopharmaceutical Company | Solutions for Unmet Medical Needs | Incyte…
incyte.com

https://incyte.com/

WEBA source for information and support. Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..

DA: 10 PA: 82 MOZ Rank: 43

Incyte - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Incyte

WEBIncyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware.

DA: 41 PA: 43 MOZ Rank: 27

Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology ... - Incyte
incyte.com

https://incyte.com/what-we-do/pharmaceutical-portfolio

WEBFeb 13, 2024 · Explore Our Science. We have a breadth of clinical programs within our portfolio across Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD), General Hematology/Oncology, Dermatology and other Inflammation & Autoimmunity (IAI), and Partnered Programs.

DA: 43 PA: 64 MOZ Rank: 2

Global Biopharmaceutical Company | Incyte.com
incyte.com

https://incyte.com/who-we-are/biopharmaceutical-research

WEBWHAT WE DO. Incyte is a global biopharmaceutical company that has created a robust and diversified portfolio of marketed products and clinical candidates in oncology, inflammation, and autoimmunity.

DA: 82 PA: 65 MOZ Rank: 91

Investors | Incyte
incyte.com

https://investor.incyte.com/

WEBMar 29, 2024 · Investors. Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

DA: 14 PA: 16 MOZ Rank: 65

Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) …
incyte.com

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-fda-approval-zynyztm-retifanlimab-dlwr

WEBMar 22, 2023 · PDF Version. — First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial. — Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds.

DA: 99 PA: 58 MOZ Rank: 4

Oncology Research | Targeted & Immunotherapy For Cancer | Incyte…
incyte.com

https://incyte.com/what-we-do/oncology

WEBIncyte is a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). We have multiple clinical trials evaluating monotherapy and combination strategies to improve and expand treatments for patients with MPNs and GVHD.

DA: 62 PA: 89 MOZ Rank: 29

Incyte Reports 2022 Fourth Quarter and Year-end Financial …
incyte.com

https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2022-fourth-quarter-and-year-end-financial

WEBFeb 7, 2023 · Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs. – Total FY'22 net product revenues grew 18% to $2.75 billion; total FY'22 revenues of $3.4 billion (+14% Y/Y) – Jakafi® (ruxolitinib) net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 …

DA: 88 PA: 84 MOZ Rank: 61

Drug Development & Scientific Innovation in Oncology and ... - Incyte
incyte.com

https://incyte.com/what-we-do/drug-development

WEBIncyte’s team of biologists and chemists are pursuing new areas in drug discovery and development in order to help patients. Drug Development & Scientific Innovation in Oncology and Inflammation & Autoimmunity | Incyte.com

DA: 15 PA: 82 MOZ Rank: 75

Incyte Corp (INCY) Stock Price & News - Google Finance
google.com

https://www.google.com/finance/quote/INCY:NASDAQ

WEBGet the latest Incyte Corp (INCY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

DA: 57 PA: 59 MOZ Rank: 85